At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 161 enrolled
Drug / intervention
NG101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis
In Brief
A Phase 2 clinical trial evaluating NG101 and Placebo for Diabetic Gastroparesis and Idiopathic Gastroparesis. Completed, enrolled 161 participants across 83 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Gastroparesis, Idiopathic Gastroparesis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedMar 10, 2020
Enrollment StartAug 1, 2020
Primary CompletionFeb 25, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.3 years ago
Interventions
NG101drug
Capsules
Placebodrug
Capsules